Evidence map›Paper›PMID 41925941›Full record

ArticleJournal of neuro-oncology2026

Therapeutic efficacy of dendritic cell vaccination in a novel syngeneic mouse model of diffuse hemispheric glioma, H3 G34-mutant.

Geoffrey C Owens, Erick M Contreras, Jenny C Kienzler, Janet Treger, Horacio Soto, Joey R Orpilla, Chloe Qiao, Julia W Chang, Alexander Lee, Wi-Jin Kim and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Geoffrey C OwensDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Erick M ContrerasDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Jenny C KienzlerDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Janet TregerDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Horacio SotoDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Joey R OrpillaDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Chloe QiaoDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Julia W ChangDivision of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Alexander LeeDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Wi-Jin KimDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Matthew Z SunDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Sophie F PeetersDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Jacob A BethelDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Aditya M KondajjiDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Eric C HollandFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Oren J BecherDepartment of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Linda M LiauDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Robert M PrinsDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Anthony C WangDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA. ACWang@mednet.ucla.edu.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
UCLA IDDRC: Translational CoreP50HD103557 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Peyman Golshani, SUMA JACOB · 2020 to 2026
$9.6M
The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancerR35CA253119 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric C. Holland · 2021 to 2026
$6.5M
UCLA Neurosurgery Research Training and Education ProgramR25NS079198 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LIAU, LINDA M · 2012 to 2021
$1.2M
NCI NIH HHS P50 CA211015NCI NIH HHS R35 CA253119NCI NIH HHS T32 CA009120NICHD NIH HHS P50 HD103557NINDS NIH HHS R25 NS079198
6 · The paper itself

Abstract

purposeThe prognosis for pediatric high-grade gliomas associated with mutations in the H3-3A gene is very poor. To investigate whether tumor lysate-pulsed dendritic cells (DC) together with checkpoint blockade might be a potential treatment modality for diffuse hemispheric glioma H3 G34-mutant (DHG), we have developed a novel syngeneic mouse model.

methodsWe used the RCAS/tv-A system to target the expression of H3G34R and PDGFβ and knock out p53 in neural progenitors in C57BL/6 neonatal mice. Three independent cell lines were obtained that expressed transcripts associated with oligodendrocyte and interneuron lineages. Lethal tumor developed following intracranial injection.

resultsTwo cycles of DC vaccination with PD-1 blockade decreased tumor burden and increased survival. In treatment resistant tumors we found higher expression of several genes involved in remodeling the extracellular matrix compared with tumors from untreated animals, suggesting a causal link to resistance to immunotherapy in this tumor model.

conclusionImmunotherapy involving autologous dendritic cells pulsed with tumor lysate and combined with anti-PD-1 antibody might be an effective treatment for DHG. Treatment failure in our tumor model is associated with increased expression of genes implicated in remodeling extracellular matrix in the tumor microenvironment.

Indexed as

Brain NeoplasmsCancer VaccinesDendritic CellsGliomaAnimalsCell Line, TumorDisease Models, AnimalImmunotherapyMiceMice, Inbred C57BLMutationProgrammed Cell Death 1 ReceptorCancer VaccinesProgrammed Cell Death 1 ReceptorDendritic cell vaccineDiffuse hemispheric gliomaExtracellular matrixPD-1 checkpoint blockadeSyngeneic mouse tumor

Identifiers

PMID41925941
PMCPMC13046641

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.